Venn Life Sciences Share News (VENN)

Venn Life Sciences, a clinical research organisation (CRO), announced on Tuesday the acquisition of Cardinal Systems SAS, a French CRO specialising in Data Management.The acquisition will allow Venn to extend its service of clinical trial management and resourcing solutions. The company will by September own 85.2% of the enlarged share capital of Cardinal.Venn has subscribed €200,000 of new ordinary shares and has purchased existing shares in Cardinal for €272,780.Venn's chief executive Tony Richardson said the acquisition "enhances our growth opportunities as a company as we can target a wider portfolio of studies and we have already encountered positive feedback from potential customers".JF